Ledger.Open graph →

SEC Form D · filed June 1, 2023

X4 Pharmaceuticals, Inc

Offering

$65.0M

Sold

$65.0M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

BOSTON, MA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (35)

Murray W. Stewart · Boston, MAExec · Director Adam S. Mostafa · Boston, MAExec Mary S. Dibiase · Boston, MAExec Paula Ragan · Boston, MAExec · Director Gary J. Bridger · Boston, MADirector David W. Mcgirr · Boston, MADirector Arthur S. Taveras · Boston, MAExec William E. Aliski · Boston, MADirector Michael S. Wyzga · Boston, MADirector Alison E. Lawton · Boston, MADirector Francoise J. De Craecker · Boston, MADirector David Finn · BOSTON, MADirector Kevin M. Swift · Corte Madera, CADirector Gary Zimmerman · Atglen, PADirector Thomas G. Hough · Warrendale, PAExec · Director Benuel Esh · Atglen, PADirector Aaron Beiler · Atglen, PAExec Brad Kalter · Jacksonville, FLExec Jacob Stoltzfus · Atglen, PAExec · Director David Platt · Atglen, PADirector Todd Denton · Little Rock, ARDirector Dustin Olson · Jacksonville, FLExec Mark Baldry · Boston, MAExec Nan V. Shen · Woburn, MAExec Dhinakarraj Gantala · Palo Alto, CAExec Ahmed Alkhateeb · Palo Alto, CADirector Cormac Conroy · Palo Alto, CADirector Bruce Hallett · Palo Alto, CADirector Jeyanandh Paramesh · Palo Alto, CAExec · Director Pcmfm, LLC · Provo, UTExec Jason Danley · Provo, UTExec · Director Pmf Iii GP, LLC · Provo, UTDirector Chris Manning · Provo, UTDirector Jeff Danley · Provo, UTDirector Mark Baldry · Boston, MAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗